Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Parallel-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of TST002 Injection in Postmenopausal Osteoporosis Patients and Middle-Aged to Older Women With Low Bone Mass

NCT07806331 is registered in ClinicalTrials.gov with Transcenta Therapeutics (Hangzhou) Co., Ltd. as lead sponsor.

NCT NCT07806331
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07806331 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Parallel-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of TST002 Injection in Postmenopausal Osteoporosis Patients and Middle-Aged to Older Women With Low Bone Mass
Lead sponsor
Transcenta Therapeutics (Hangzhou) Co., Ltd.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
October 31, 2028
Enrollment
110 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

low bone mass, postmenopausal osteoporosis